TRIAL DETAIL

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

Drug:
Trial Name:
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
2
Start Date 03/01/2012
Age of Trial (yrs) 9.8
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor + MEK inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CMEK162X2109, EUDRACT: 2011-002578-21
Sponsor:
Array BioPharma
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Combined inhibition of MAP kinase and KIT signaling effectively destabilizes the ETV1 protein and synergistically suppresses GIST tumorigenesis
 

Trial Sites

Name
Address
City
State
Zip
Country
100 Blossom St
Charlestown
MA
02114
USA
2000 Circle of Hope
Salt Lake City
UT
84103
USA
Grattan Street
Parkville
Victoria
3050
Australia
Villejuif
Val de Narne
94805
France
119-129
Barcelona
08035
Spain
Surrey
sM2 5PT
UK
La Jolla
CA
92093
USA
675 North St. Clair
Chicago
IL
60611
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
Bellinzona
Switzerland